PharmAbcine - Bispecific Antibody Engineering Service
The dual target antibody platform technology of PharmAbcine is based on the fully human antibody candidates selected from HuPhage biopanning process. Depending on antigen presentation patterns on target cell types and the related drug MOA, various bispecific platforms (DIG-body, PIG-body and TIG-body) are adopted in our antibody engineering strategy. Currently, immuno-oncology assets like PMC-122a (anti-PD-L1 x SIRPa) and PMC-122b (anti-PD-L1 x anti-CD47) are currently under early development stage.
Most popular related searches
No reviews were found for PharmAbcine - Bispecific Antibody Engineering Service. Be the first to review!